How Neurologists' Prescribe Multiple Sclerosis Drugs to the Target MS Patient

DURHAM, N.C. - Dec. 6, 2022 - PRLog -- The two key factors that neurologists consider when prescribing multiple sclerosis treatments are the MS patient's disease severity, as well as their history with previous MS medications, according to new insights published by market research agency Vivisum Partners.

Across all available multiple sclerosis therapies, healthcare providers (HCPs) stratify patients primarily between mild to moderate and moderate to severe disease. Low or high disease activity MS patients are never the primary patient type for certain brands, such as Tecfidera, Aubagio and Mavenclad. According to Multiple Sclerosis Target Patient Analysis, Tecfidera continues to provide neurologists with a frequently used first-line DMT option to treat mild to moderate patients who are treatment-naïve. Few newer therapies compete for this patient type.

For individuals who need to escalate their treatment, neurologists will look to a different group of therapies for these MS patients. Gilenya, for example, is a good intermediate option that provides a balance of efficacy, safety, and convenience for those patients who are mild to moderate and have failed 1 disease modifying therapy (DMT). Zeposia is also competing for this type of MS patient.

"Neurologists are split between using Gilenya for patients with mild to moderate activity vs. moderate to severe activity," said Ellen Hart, director and multiple sclerosis strategist at Vivisum Partners. "Patients with low activity or high activity are better suited for other products."

Multiple Sclerosis Target Patient Analysis, published in October 2022 by Vivisum Partners, breaks down common MS patient characteristics for 12 branded multiple sclerosis drugs and discusses how well each brand aligns with the following patient traits:

• Disease severity
• Treatment history
• Lifestyle
• Age
• Comorbidities

The market research contained in Multiple Sclerosis Target Patient Analysis, found at http://vivisumpartners.com/reports/multiple-sclerosis-tar..., supports strategy development for both existing and developing multiple sclerosis brands. The report features include:

• Typical patient map illustrating key differences in target patients for existing branded multiple sclerosis drugs
• Breakdown of typical MS patient archetypes aligned with top therapies for each persona.
• Analysis of prescribing trends for existing branded MS treatments
• Comprehensive patient profiles for 12 branded MS treatments

ABOUT VIVISUM PARTNERS, LLC

Vivisum Partners, LLC is a market research agency providing strategic consulting around marketing and brand building. Vivisum provides facilitated discovery using market research methodologies and critical thinking processes. The actionable market research insights that Vivisum provides enable clients to shape their commercial strategies.